Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) saw an uptick in trading volume on Thursday . 4,199,483 shares changed hands during mid-day trading, an increase of 341% from the previous session’s volume of 951,718 shares.The stock last traded at $0.71 and had previously closed at $0.60.
Separately, Maxim Group reiterated a “buy” rating and issued a $4.00 price objective on shares of ContraVir Pharmaceuticals in a research note on Thursday, August 24th.
The firm’s 50 day moving average is $0.53 and its 200-day moving average is $0.75. The company’s market capitalization is $55.08 million.
A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. lifted its holdings in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,414,475 shares of the biopharmaceutical company’s stock after buying an additional 366,192 shares during the period. Vanguard Group Inc. owned approximately 3.79% of ContraVir Pharmaceuticals worth $1,400,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.97% of the company’s stock.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.
Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.